Perimeter Capital Partners’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Perimeter Capital Partners’s Portfolio SGNT Stock Details SGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-8,050	Closed	-$250K	–	79
2014 Q3	$250K	Sell	8,050 -44,331	-85%	-$1.2M	0.42%	62
2014 Q2	$1.35M	Sell	52,381 -20,961	-29%	-$466K	0.69%	59
2014 Q1	$1.71M	Sell	73,342 -38,747	-35%	-$847K	0.85%	26
2013 Q4	$2.85M	Sell	112,089 -136,804	-55%	-$3.09M	1.4%	1
2013 Q3	$5.08M	Buy	+248,893	New	+$5.54M	0.94%	13

Other funds holding SGNT

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Perimeter Capital Partners's SGNT Position: Q4 2014 in Review

Perimeter Capital Partners sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q4 2014, closing a stake of 8,050 shares — an estimated $250K sold.

Perimeter Capital Partners first reported a position in SGNT in Q3 2013 and held it in 5 quarters. The position peaked at $5.08M in Q3 2013. 131 funds tracked by Wall St. Rank hold SGNT as of Q4 2014.

Perimeter Capital Partners reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q4 2014 after selling out during the quarter.
Perimeter Capital Partners sold 8,050 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q4 2014, an estimated $250K.
Perimeter Capital Partners first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2013 and held it in 5 quarters.
Perimeter Capital Partners's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $5.08M in Q3 2013.
131 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q4 2014.

Based on Perimeter Capital Partners's 13F filing for Q4 2014.